Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lung Neoplasms 10Carcinoma, Non-Small-Cell Lung 9Fallopian Tube Neoplasms 7Ovarian Neoplasms 6Colorectal Neoplasms 5Urinary Bladder Neoplasms 4Pancreatic Neoplasms 4Melanoma 4Carcinoma, Hepatocellular 4Lymphoma, Large B-Cell, Diffuse 3Glioblastoma 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Brain Neoplasms 3Urethral Neoplasms 2Ureteral Neoplasms 2Thyroid Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Rectal Neoplasms 2Prostatic Neoplasms 2Neoplasm Metastasis 2Nasopharyngeal Carcinoma 2Multiple Myeloma 2Lymphoid Interstitial Pneumonia 2Leukemia, Lymphocytic, Chronic, B-Cell 2Carcinoma, Neuroendocrine 2Carcinoma 2Burkitt Lymphoma 2Brenner Tumor 2Breast Neoplasms 2

Interventions

Rituximab 16Cyclophosphamide 16Prednisone 7Doxorubicin 7pirtobrutinib 6fludarabine 6Vincristine 6Lenalidomide 6venetoclax 5pembrolizumab 5fludarabine phosphate 5Etoposide 5Bendamustine Hydrochloride 5ibrutinib 4acalabrutinib 4Specimen Handling 4Magnetic Resonance Spectroscopy 4Dexamethasone 4CT-P10 4polatuzumab vedotin 3etoposide phosphate 3Immunotherapy, Adoptive 3tazemetostat 2liposomal doxorubicin 2Nivolumab 2Injections 2Ifosfamide 2Gemcitabine 2Cisplatin 2Carboplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Lymphoma, B-Cell × Disulfides × Clear all
NCT03038672 2026-05-12

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

National Cancer Institute (NCI)

Phase 2 Active not recruiting
54 enrolled 12 charts
Lymphoid

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphomatoid Granulomatosis, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Primary Effusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡